Sessions

Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Morning Briefing
CellGenix Briefing
How Digitizing Your Quality Management System is Important in a Workforce Shortage to Meet Regulatory Compliance
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Be the Match Biotherapies Briefing
Future-Proofing Cell Therapy Production
Industrialisation and Commercialisation in Cell and Gene Therapy: From Platform Technologies to Manufacturing Infrastructure and Beyond

Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made

27 Jan 2022
12:30
Briefing Room
SPONSORED BY
Resilience

The technology for manufacturing complex medicines like cell and gene therapy hasn’t kept pace with the wave of scientific discoveries fueling them. Because many approaches to treating rare and life-threatening diseases are so new, the process of making them hasn’t progressed beyond methods only meant for small batch, often originating in academic labs. As clinical proof of concept is recognized, advanced to later stage development becomes more challenging and introduces regulatory implications often slowing the pace of approval of these life-saving therapies.

 

In this panel discussion, we will take a deeper look into what has hindered growth and scalability of these exciting therapies, and how disruptive technology and cross-industry partnerships are driving change in this young and exciting field of medicine.

 

  • Best practices for successful partnerships between industries, clients, service providers, technology partners, and academics
  • Viral vector technology platforms
  • Cell therapy technology platforms
  • Investment and risk-sharing concepts in the development of novel therapeutics
  • Product life cycle management